CR
CREO.LSE Creo Medical Group PLC
- Market cap
- GBX 50.5M
- P/E
- -
- P/B
- 1.06x
- ROE
- -59.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is CREO.LSE undervalued?
Graham numberThe Graham number of Creo Medical Group PLC cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Creo Medical Group PLC fundamental analysis
No fundamental analysis for Creo Medical Group PLC yet.
Creo Medical Group PLC stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Creo Medical Group PLC
Creo Medical Group PLC, through its subsidiaries, engages in the research, development, manufacture, and sale of medical devices and instruments for clinics and hospitals in the United Kingdom. It develops CROMA, an energy platform that combines bipolar radiofrequency for precise localized cutting and microwave energy for controlled coagulation, to provide physicians with controllable devices delivered through an endoscope. It also offers Speedboat Inject, an energy multimod…
Full company profileCreo Medical Group PLC financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Creo Medical Group PLC annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 508K | 0.00 | - | 13.5K | 9.43M | 25.2M | 27.2M | 4.00M | 4.00M | 6.00M | 12.8M |
| Gross Profit | 508K | -142K | -332K | -637K | 2.44M | 9.02M | 10.0M | 15.3M | 1.90M | 1.40M | 4.40M |
| Operating Income | -1.87M | -8.90M | -11.9M | -18.9M | -23.4M | -30.0M | -30.8M | -24.8M | -28.8M | -20.7M | -32.0M |
| EBITDA | - | -8.76M | -11.6M | -18.0M | -21.8M | -27.5M | -27.6M | -20.7M | -26.1M | -19.7M | -30.4M |
| Net Income | -1.61M | -7.77M | -9.87M | -15.9M | -20.3M | -24.6M | -26.9M | -21.7M | -28.7M | 5.30M | -28.8M |
| EPS | - | -0.12 | -0.11 | -0.13 | -0.13 | -0.14 | -0.14 | -0.07 | -0.08 | 0.01 | -0.07 |
| Balance Sheet | |||||||||||
| Total Assets | 2.42M | 16.1M | 49.7M | 88.3M | 92.5M | 101M | 75.3M | 76.6M | 65.0M | 59.1M | 56.8M |
| Total Liabilities | 789K | 1.47M | 2.03M | 5.60M | 29.7M | 27.3M | 25.9M | 16.8M | 22.6M | 9.10M | 8.60M |
| Shareholders' Equity | 1.63M | 14.7M | 47.7M | 82.7M | 62.8M | 73.3M | 49.4M | 59.8M | 42.4M | 50.0M | 48.2M |
| Cash & Short-term Investments | 823K | 13.7M | 44.6M | 81.0M | 45.1M | 43.5M | 13.1M | 18.5M | 8.70M | 12.4M | 7.40M |
| Total Debt | 15.0K | 15.2K | 433K | 717K | 12.4M | 10.6M | 11.7M | 8.30M | 4.40M | 4.10M | 3.90M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -1.64M | -6.91M | -14.2M | -11.5M | -16.1M | -26.0M | -25.0M | -21.6M | -22.2M | -18.6M | -37.6M |
| Capital Expenditure | 87.0K | 226K | 1.39M | 1.12M | 576K | 6.12M | 3.27M | 1.20M | 400K | 900K | 0.00 |
| Free Cash Flow | - | -7.14M | -15.6M | -12.7M | -16.7M | -32.1M | -28.3M | -22.8M | -22.6M | -20.0M | -37.6M |
| Ratios | |||||||||||
| ROE | -99.0% | -53.0% | -20.7% | -19.2% | -32.3% | -33.5% | -54.5% | -36.3% | -67.7% | 10.6% | -59.8% |
| ROA | -66.7% | -48.2% | -19.8% | -18.0% | -22.0% | -24.4% | -35.8% | -28.3% | -44.2% | 9.0% | -50.7% |
| Net Profit Margin | -317.4% | - | - | -118,096.6% | -215.5% | -97.8% | -99.1% | -542.5% | -717.5% | 88.3% | -225.0% |
| Debt to Equity | 0.01x | 0.00x | 0.01x | 0.01x | 0.20x | 0.14x | 0.24x | 0.14x | 0.10x | 0.08x | 0.08x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Creo Medical Group PLC dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | GBP 20.0M | 0.32 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Creo Medical Group PLC
- Insiders 6.94%
- Institutions 45.41%
- Public & others 47.65%
- Shares outstanding 449M
- Free float 383M
Creo Medical Group PLC company profile
- Company name
- Creo Medical Group PLC
- Ticker
- CREO.LSE
- ISIN
- GB00BZ1BLL44
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 104
- Fiscal year end
- June
- Address
- Creo House, Chepstow, United Kingdom, NP16 5UH
- Phone
- 44 12 9160 6005
- Website
- creomedical.com
About Creo Medical Group PLC
Creo Medical Group PLC, through its subsidiaries, engages in the research, development, manufacture, and sale of medical devices and instruments for clinics and hospitals in the United Kingdom. It develops CROMA, an energy platform that combines bipolar radiofrequency for precise localized cutting and microwave energy for controlled coagulation, to provide physicians with controllable devices delivered through an endoscope. It also offers Speedboat Inject, an energy multimodal instrument for endoscopy; MicroBlate Fine, a microwave needle ablation device; MicroBlate Flex, a microwave ablation device designed for soft tissue ablation; and SpydrBlade Flex, a multi-modal endoscopic scissor-type device. In addition, the company provides injection needles, hemostatic clips, snares, and forceps, as well as other products for gastroenterology, pulmonology, and urology. Further, it offers products for diagnostic, therapeutic, and hygiene purposes. Creo Medical Group PLC was founded in 2003 and is headquartered in Chepstow, the United Kingdom.
Creo Medical Group PLC management
5- Mr. Craig Jonathan GullifordCEO & Executive Director · born 1970
- Prof. Christopher Paul HancockFounder & CTO · born 1967
- Mr. Richard John Rees ACACFO & Executive Director · born 1976
- Mr. David Gerard WoodsChief Commercial Officer · born 1965
- Mr. Richard Gary CravenSecretary